Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924
about
Cellular deficiency in the RGS10 protein facilitates chemoresistant ovarian cancerUbiquitylation, neddylation and the DNA damage responseChemogenomic Study of Carboplatin in Saccharomyces cerevisiae: Inhibition of the NEDDylation Process Overcomes Cellular Resistance Mediated by HuR and Cullin ProteinsInactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.Glutamine promotes ovarian cancer cell proliferation through the mTOR/S6 pathway.Modeling platinum sensitive and resistant high-grade serous ovarian cancer: development and applications of experimental systems.ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer.Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.Targeting cullin-RING ligases for cancer treatment: rationales, advances and therapeutic implications.Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer.Targeting Neddylation pathways to inactivate cullin-RING ligases for anticancer therapyCombined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target.The NEDD8-activating enzyme inhibitor MLN4924 disrupts nucleotide metabolism and augments the efficacy of cytarabineInactivating UBE2M impacts the DNA damage response and genome integrity involving multiple cullin ligases.It is not all about BRCA: Cullin-Ring ubiquitin Ligases in ovarian cancer.Synergistic inhibition of autophagy and neddylation pathways as a novel therapeutic approach for targeting liver cancer.MLN4924 Synergistically Enhances Cisplatin-induced Cytotoxicity via JNK and Bcl-xL Pathways in Human Urothelial CarcinomaThe NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.Suppression of tumor angiogenesis by targeting the protein neddylation pathway.MLN4924 therapy as a novel approach in cancer treatment modalities.Pharmacological targeting of RAD6 enzyme-mediated translesion synthesis overcomes resistance to platinum-based drugs.Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924).The Neddylation Inhibitor Pevonedistat (MLN4924) Suppresses and Radiosensitizes Head and Neck Squamous Carcinoma Cells and Tumors.Pevonedistat, a first-in-class NEDD8-activating enzyme (NAE) inhibitor, combined with azacitidine, in patients with AML.MLN4924 neddylation inhibitor promotes cell death in paclitaxel-resistant human lung adenocarcinoma cells.Neddylation inhibitor MLN4924 induces G2 cell cycle arrest, DNA damage and sensitizes esophageal squamous cell carcinoma cells to cisplatin.Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance.Regulation of Mammalian DNA Replication via the Ubiquitin-Proteasome System.
P2860
Q26796258-E0806849-6457-41B1-BCD3-9E856C752E1EQ28087342-DBF30DCD-576E-4089-81DD-3551FCEB95DAQ28551657-DEB6A5D7-8BED-45D2-B434-4F781D9174EEQ30276526-57841381-7676-4EC9-B1FF-506D2E247918Q30371587-F4FD5C09-F530-49FD-8311-80DD9DAB558FQ33641924-11A50138-8105-4A72-8F5E-ED20AB01D31DQ33648465-48C4E630-3F9F-4872-95F6-959DDE9B1A3FQ33983255-754903CB-B854-4838-BCAC-AA93EFBFE9EFQ34043821-2E4C6696-3731-464F-B493-B5141CE902F8Q34543264-EC91AFFB-9132-4C4D-A476-F642FA286949Q34563129-F68BF18B-AD56-4F9B-B6D3-01C84E994FD2Q34978486-F4FDF405-0156-4B90-B2F0-1C1B73A6CCF9Q34979606-6809043F-E75A-4E07-9A5D-972A7CD46D92Q35207086-E1752B65-9DA8-4B59-A069-70896575060BQ35678132-2ABF0DBC-FDB0-4083-BEBE-CD5796862E51Q35832285-CD717460-458C-4EEF-9A60-1928528A4C9BQ36305476-467A6B27-5224-4D9B-BE2A-8317096986ABQ36876973-7C0CACFD-2F60-4908-92BC-ABB0C5CEF671Q37620640-F8D78F6F-E681-467B-B615-1EFA473F44E7Q38570362-45EB1597-C53F-4A41-B142-415AB3E96739Q38704026-31CF3BE5-1CB9-4285-8E8C-2C59555B4E7BQ38736706-700CED92-7C06-4620-9CEE-2D8C3784E476Q40071281-64367760-70C4-47CF-99A8-958B3AD0FB11Q48216923-31A4AAD4-EDE4-4432-822E-AE75EAFE6D5FQ48517497-226C4DC2-9E7A-492A-8E04-206975BA6C81Q49456490-26E3BE6C-B486-4C23-B84F-E71B6583B0A8Q52584568-FFE00910-252C-4CB5-AF55-549CFF47670EQ55239552-81E7289B-AF46-46A0-898F-A351CDB54529
P2860
Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924
description
2013 nî lūn-bûn
@nan
2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Overcoming platinum resistance ...... neddylation inhibitor MLN4924
@ast
Overcoming platinum resistance ...... neddylation inhibitor MLN4924
@en
type
label
Overcoming platinum resistance ...... neddylation inhibitor MLN4924
@ast
Overcoming platinum resistance ...... neddylation inhibitor MLN4924
@en
prefLabel
Overcoming platinum resistance ...... neddylation inhibitor MLN4924
@ast
Overcoming platinum resistance ...... neddylation inhibitor MLN4924
@en
P2093
P2860
P1476
Overcoming platinum resistance ...... neddylation inhibitor MLN4924
@en
P2093
Allison J Berger
Amir A Jazaeri
Jennifer L Bryant
Jonghoon Park
Mark R Conaway
Michael A Milhollen
Peter G Smith
Susan C Modesitt
P2860
P304
P356
10.1158/1535-7163.MCT-12-1028
P577
2013-08-12T00:00:00Z